Answers are grounded in this paper and cite their sources.
In summary, this article serves to provide a more uniform set of criteria for clinical trials and reporting outcomes used in designing stroke trials involving intra-arterial thrombolytic agents, either alone or in combination with other therapies. It is anticipated that by having a more uniform set of reporting standards, more meaningful analysis of the data and the literature will be able to be achieved.
No takes yet. Share an insight, caveat, or question.
Higashida et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: